<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article305</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/Twice-daily_RT_for_SCLC" style="display:block; margin-bottom:10px;">Twice-daily RT for SCLC Original</a></li>
<h2><strong>Twice-daily RT for SCLC</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Twice-Daily versus Once-Daily Thoracic Radiotherapy in Limited Small-Cell Lung Cancer Treated with Cisplatin and Etoposide". New England Journal of Medicine. 1999. 340(4):265-271. PubMed • Full text • PDF<br/>
<br/>
<h2><strong>Contents</strong></h2><br/>
1 Clinical Question<br/>
2 Bottom Line<br/>
3 Major Points<br/>
4 Design<br/>
5 Population<br/>
5.1 Inclusion Criteria<br/>
5.2 Exclusion Criteria<br/>
5.3 Baseline Characteristics<br/>
6 Interventions<br/>
7 Outcomes<br/>
7.1 Primary Outcome<br/>
7.2 Secondary Outcomes<br/>
8 Funding<br/>
9 Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
In patients with limited small-cell lung cancer, does twice-daily thoracic radiotherapy improve survival compared with once-daily thoracic radiotherapy when both are combined with cisplatin and etoposide?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
In patients with limited small-cell lung cancer, twice-daily thoracic radiotherapy significantly improved survival compared with once-daily therapy when combined with cisplatin and etoposide, but increased the risk of grade 3 esophagitis.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/>
Twice-daily accelerated thoracic radiotherapy, when combined with cisplatin and etoposide, offers a survival advantage over once-daily radiotherapy in limited small-cell lung cancer, with a 10% higher 5-year survival rate. <br/>
<br/>
<h2><strong>Design</strong></h2><br/>
- Multicenter, randomized, controlled trial<br/>
- N=417 patients with limited small-cell lung cancer<br/>
- Once-daily thoracic radiotherapy (n=206)<br/>
- Twice-daily thoracic radiotherapy (n=211)<br/>
- Setting: Multiple institutions<br/>
- Enrollment: May 1989 to July 1992<br/>
- Mean follow-up: Almost 8 years<br/>
- Analysis: Intention-to-treat<br/>
- Primary outcome: Overall survival<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
Inclusion Criteria<br/>
- Small-cell lung cancer clinically confined to one hemithorax (limited)<br/>
- Adequate organ function and performance status<br/>
<br/>
Exclusion Criteria<br/>
- Pleural effusions visible on chest films, symptomatic cardiac disease, previous chemotherapy or radiotherapy, prior cancer<br/>
<br/>
Baseline Characteristics<br/>
- Median age: 63 years (once-daily), 61 years (twice-daily)<br/>
- Sex: 40% female<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- Four cycles of chemotherapy with cisplatin (60 mg/m² on day 1) and etoposide (120 mg/m² on days 1-3) every 21 days<br/>
- Thoracic radiotherapy 45 Gy total dose, delivered as<br/>
   - Once-daily (1.8 Gy per day) over five weeks<br/>
   - Twice-daily (1.5 Gy per treatment) over three weeks<br/>
- Prophylactic cranial irradiation offered to patients with complete response<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcome<br/>
- Median survival: 19 months for once-daily, 23 months for twice-daily<br/>
- 2-year survival rate: 41% for once-daily, 47% for twice-daily<br/>
- 5-year survival rate: 16% for once-daily, 26% for twice-daily<br/>
<br/>
Secondary Outcomes<br/>
- Grade 3 esophagitis: 11% for once-daily, 27% for twice-daily<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
- Public Health Service grants from the National Cancer Institute, National Institutes of Health, and Department of Health and Human Services<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
- Full text article available on the New England Journal of Medicine website
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
